Top

Published in:

01-08-2014 | Original Article

Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression

Authors: Anthony L. Traboulsee, Cecily Q. Bernales, Jay P. Ross, Joshua D. Lee, A. Dessa Sadovnick, Carles Vilariño-Güell

Published in: Neurogenetics | Issue 3/2014

Abstract

Multiple sclerosis (MS) is a common demyelinating neurodegenerative disease with a strong genetic component. Previous studies have associated genetic variants in IL2RA and IL7R in the pathophysiology of the disease. In this study, we describe the association between IL2RA (rs2104286) and IL7R (rs6897932) in the Canadian population. Genotyping 1,978 MS patients and 830 controls failed to identify any significant association between these variants and disease risk. However, stratified analysis for family history of disease and disease course identified a trend towards association for IL2RA in patients without a family history (p = 0.05; odds ratio = 0.77) and a significant association between IL7R and patients who developed progressive MS (PrMS) (p = 0.002; odds ratio = 0.73). Although not statistically significant, the effect of IL2RA (rs2104286) in patients without a family history of MS indicates that the genetic components for familial and sporadic disease are perhaps distinct. This data suggests that the onset of sporadic disease is likely determined by a large number of variants of small effect, whereas MS in patients with a family history of disease is caused by a few deleterious variants. In addition, the significant association between PrMS and rs6897932 indicates that IL7R may not be disease-causing but a determinant of disease course. Further characterization of the effect of IL2RA and IL7R genetic variants in defined MS subtypes is warranted to evaluate the effect of these genes on specific clinical outcomes and to further elucidate the mechanisms of disease onset and progression.

Wade BJ (2014) Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int 2014:124578. doi:10.1155/2014/124578 PubMedCentralPubMedCrossRef

Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7(3):268–277PubMedCrossRef

Noseworthy JH (1999) Progress in determining the causes and treatment of multiple sclerosis. Nature 399(6738 Suppl):A40–A47PubMedCrossRef

Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214–219. doi:10.1038/nature10251 PubMedCentralPubMedCrossRef

Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C et al (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45(11):1353–1360. doi:10.1038/ng.2770 PubMedCrossRef

Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al (2007) Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39(9):1083–1091. doi:10.1038/ng2103 PubMedCrossRef

Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357(9):851–862. doi:10.1056/NEJMoa073493 PubMedCrossRef

Wang LM, Zhang DM, Xu YM, Sun SL (2011) Interleukin 2 receptor alpha gene polymorphism and risk of multiple sclerosis: a meta-analysis. J Int Med Res 39(5):1625–1635PubMedCrossRef

Zhang R, Duan L, Jiang Y, Zhang X, Sun P, Li J, Zhang M, Tang G, Wang X, Li X (2011) Association between the IL7R T244I polymorphism and multiple sclerosis: a meta-analysis. Mol Biol Rep 38(8):5079–5084. doi:10.1007/s11033-010-0654-5 PubMedCrossRef

10.

Hoppenbrouwers IA, Aulchenko YS, Janssens AC, Ramagopalan SV, Broer L, Kayser M, Ebers GC, Oostra BA, van Duijn CM, Hintzen RQ (2009) Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J Hum Genet 54(11):676–680. doi:10.1038/jhg.2009.96 PubMedCrossRef

11.

Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT (2009) Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun 32(2):110–115. doi:10.1016/j.jaut.2009.01.002 PubMedCrossRef

12.

Sadovnick AD, Risch NJ, Ebers GC (1998) Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. Can J Neurol Sci 25(3):216–221PubMed

13.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231. doi:10.1002/ana.410130302 PubMedCrossRef

14.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef

15.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846. doi:10.1002/ana.20703 PubMedCrossRef

16.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMedCrossRef

17.

Trinh J, Vilarino-Guell C, Donald A, Shah B, Yu I, Szu-Tu C, Aasly JO, Wu RM, Hentati F, Rajput AH, Rajput A, Farrer MJ (2013) STX6 rs1411478 is not associated with increased risk of Parkinson's disease. Parkinsonism Relat Disord 19(5):563–565. doi:10.1016/j.parkreldis.2013.01.019 PubMedCrossRef

18.

Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, Durum SK (2005) Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16(4–5):513–533PubMedCrossRef

19.

Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4(9):665–674. doi:10.1038/nri1435 PubMedCrossRef

20.

Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747–753. doi:10.1038/nature08494 PubMedCentralPubMedCrossRef

21.

Booth DR, Arthur AT, Teutsch SM, Bye C, Rubio J, Armati PJ, Pollard JD, Heard RN, Stewart GJ (2005) Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med (Berlin) 83(10):822–830. doi:10.1007/s00109-005-0684-y CrossRef

22.

Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J (2007) Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39(9):1108–1113PubMedCrossRef

23.

Zhang Z, Duvefelt K, Svensson F, Masterman T, Jonasdottir G, Salter H, Emahazion T, Hellgren D, Falk G, Olsson T, Hillert J, Anvret M (2005) Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immunol 6(2):145–152CrossRef

24.

Qiu W, Pham K, James I, Nolan D, Castley A, Christiansen FT, Czarniak P, Luo Y, Wu J, Garlepp M, Wilton S, Carroll WM, Mastaglia FL, Kermode AG (2013) The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort. J Neuroimmunol 261(1–2):92–97. doi:10.1016/j.jneuroim.2013.04.022 PubMedCrossRef

25.

O'Doherty C, Kantarci O, Vandenbroeck K (2008) IL7RA polymorphisms and susceptibility to multiple sclerosis. N Engl J Med 358(7):753–754. doi:10.1056/NEJMc0707553 PubMedCrossRef

26.

McKay FC, Swain LI, Schibeci SD, Rubio JP, Kilpatrick TJ, Heard RN, Stewart GJ, Booth DR (2008) CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. J Autoimmun 31(1):52–58. doi:10.1016/j.jaut.2008.02.003 PubMedCrossRef

Title: Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression
Authors: Anthony L. Traboulsee
Cecily Q. Bernales
Jay P. Ross
Joshua D. Lee
A. Dessa Sadovnick
Carles Vilariño-Güell
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Neurogenetics / Issue 3/2014
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-014-0403-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family

AIMP1 deficiency presents as a cortical neurodegenerative disease with infantile onset

Recessive C10orf2 mutations in a family with infantile-onset spinocerebellar ataxia, sensorimotor polyneuropathy, and myopathy

Coexistence of DMPK gene expansion and CLCN1 missense mutation in the same patient

‘Neuroinflammation’ differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared

Novel recessive myotilin mutation causes severe myofibrillar myopathy